Comparative outcomes of intralesional collagenase injection for Peyronie's disease: acute vs. stable phase treatment.

Abstract

Collagenase clostridium histolyticum (CCH) was FDA-approved for treating Peyronie's Disease (PD), demonstrating significant curvature improvement in patients during the stable phase of disease. In this retrospective cohort study, we aimed to assess the safety and effectiveness of intralesional CCH injections during the acute phase of PD. We retrospectively evaluated all men who received intralesional CCH for PD at a single academic institution between July 2017 and January 2023, focusing on patient demographics, comorbidities, pre- and post-treatment curvature, and adverse events. Patients in the acute phase had symptoms for ≤ 12 months with penile pain and/or curvature changes. A total of 100 patients treated with intralesional CCH injections for PD were included. Percent change in penile curvature was not significantly different between acute and stable phases (37.02 vs. 34.01%, p = 0.57). A total of 55 patients (76.39%) in the stable phase and 23 patients (82.14%) in the acute phase showed improvement in curvature, with no significant differences in curvature outcomes or adverse events between the two groups. This study contributes to the growing evidence that intralesional CCH treatment during the acute phase of PD is safe and effective.